Who are Aktis Oncology, Inc.'s main suppliers?

Aktis Oncology, Inc. (AKTS) key suppliers include: MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC, UBS-OPTIMUS-FOUNDATION. View the full supplier network at chainsifter.com/chain/AKTS.

Who are Aktis Oncology, Inc.'s major customers?

Aktis Oncology, Inc. (AKTS) key customers include: ELI-LILLY. View the full customer network at chainsifter.com/chain/AKTS.

What sector is Aktis Oncology, Inc. in?

Aktis Oncology, Inc. (AKTS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

AKTS Supply Chain: Aktis Oncology, Inc. Suppliers & Customers

2Suppliers

1Customers

2Debt Items

20Related Chains

Aktis Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC	MPM-ONCOLOGY-CHARITABLE-FOUNDATION-INC	90%	Pursuant to the Royalty Transfer Agreement, the Company will pay 0.5 % of annual global net sales to each of the Charitable Foundations, for a total of 1.0 % of net sales, subject to customary reduct…
UBS-OPTIMUS-FOUNDATION	UBS-OPTIMUS-FOUNDATION	90%	Pursuant to the Royalty Transfer Agreement, the Company will pay 0.5 % of annual global net sales to each of the Charitable Foundations, for a total of 1.0 % of net sales, subject to customary reduct…

Aktis Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
ELI-LILLY	ELI-LILLY	92%	In addition, if Eli Lilly successfully commercializes a therapeutic or diagnostic product under the Collaboration Agreement, Eli Lilly is required to pay us tiered royalties of up to 10% based on ann…

Aktis Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
AKTS-DEBT	Debt stack $11.6M	90%	Market cache reports total debt of $11.6M.
AKTS-DEBT-59495	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2026-03-31.

Aktis Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Aktis Oncology, Inc..

Aktis Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
AKTS-OWNER-BARCLAYS-PLC	BARCLAYS PLC	90%	13F overlay lists BARCLAYS PLC as top holder; 2 tracked holders.

Aktis Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
VEEV	Veeva Systems Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
ACRS	Aclaris Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
VNDA	Vanda Pharmaceuticals Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2
ACIU	AC Immune SA	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
VIVS	VivoSim Labs, Inc.	100.00	2

Aktis Oncology, Inc. Supply Chain